These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 29574354)

  • 1. Letter to the editor to the paper: "Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis".
    Ziemssen T; Limmroth V
    Mult Scler Relat Disord; 2018 May; 22():57-58. PubMed ID: 29574354
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis.
    Akbulak RÖ; Rosenkranz SC; Schaeffer BN; Pinnschmidt HO; Willems S; Heesen C; Hoffmann BA
    Mult Scler Relat Disord; 2018 Jan; 19():44-49. PubMed ID: 29127856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis.
    Simula S; Laitinen T; Laitinen TM; Tarkiainen T; Hartikainen P; Hartikainen JE
    Mult Scler; 2016 Jul; 22(8):1080-5. PubMed ID: 26362903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart rate variability predicts the magnitude of heart rate decrease after fingolimod initiation.
    Simula S; Laitinen TP; Laitinen TM; Hartikainen P; Hartikainen JE
    Mult Scler Relat Disord; 2016 Nov; 10():86-89. PubMed ID: 27919506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac repolarization during fingolimod treatment in patients with relapsing-remitting multiple sclerosis.
    Laiho A; Laitinen TM; Hartikainen P; Hartikainen JEK; Laitinen TP; Simula S
    Brain Behav; 2018 Feb; 8(2):e00925. PubMed ID: 29484274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Three Months Fingolimod Therapy on Heart Rate.
    Simula S; Laitinen T; Laitinen TM; Tarkiainen T; Hartikainen JE; Hartikainen P
    J Neuroimmune Pharmacol; 2015 Dec; 10(4):651-4. PubMed ID: 26092537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart rate variability decreases after 3 months of sustained treatment with fingolimod.
    Vehoff J; Haegele-Link S; Humm A; Kaegi G; Mueller SK; Sauter R; Tettenborn BE; Hundsberger T
    J Neurol; 2017 Nov; 264(11):2313-2317. PubMed ID: 28993873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
    Meissner A; Limmroth V
    Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to letter regarding article 'Fingolimod effects on left ventricular function in multiple sclerosis'.
    Racca V; Di Rienzo M; Cavarretta R; Toccafondi A; Vaini E; Ferratini M; Rovaris M
    Mult Scler; 2016 Apr; 22(5):708-9. PubMed ID: 26359278
    [No Abstract]   [Full Text] [Related]  

  • 10. The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis.
    Datt J; Baldock L; Pull E; Webber B
    Mult Scler Relat Disord; 2016 Jan; 5():40-6. PubMed ID: 26856942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The autonomic balance predicts cardiac responses after the first dose of fingolimod.
    Rossi S; Rocchi C; Studer V; Motta C; Lauretti B; Germani G; Macchiarulo G; Marfia GA; Centonze D
    Mult Scler; 2015 Feb; 21(2):206-16. PubMed ID: 24957049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Safety and Patient Profile of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina.
    Rojas JI; Patrucco L; Miguez J; Cristiano E
    Clin Neuropharmacol; 2017; 40(6):251-254. PubMed ID: 28976408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation.
    Andrade C
    JAMA Neurol; 2016 Nov; 73(11):1375-1376. PubMed ID: 27669463
    [No Abstract]   [Full Text] [Related]  

  • 14. Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation.
    Merschhemke M; Tomic D; Putzki N
    JAMA Neurol; 2016 Nov; 73(11):1375. PubMed ID: 27669336
    [No Abstract]   [Full Text] [Related]  

  • 15. Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation-Reply.
    Hatcher SE; Waubant E; Graves JS
    JAMA Neurol; 2016 Nov; 73(11):1376. PubMed ID: 27669526
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.
    Paolicelli D; Manni A; Direnzo V; D'Onghia M; Tortorella C; Zoccolella S; Trojano M
    J Clin Pharmacol; 2015 Oct; 55(10):1131-6. PubMed ID: 25903516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent drug holidays in fingolimod therapy for multiple sclerosis.
    Tanaka M; Kinoshita M; Tanaka K
    Mult Scler; 2018 Feb; 24(2):236-237. PubMed ID: 28741980
    [No Abstract]   [Full Text] [Related]  

  • 18. Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing.
    Hilz MJ; Intravooth T; Moeller S; Wang R; Lee DH; Koehn J; Linker RA
    PLoS One; 2015; 10(7):e0132139. PubMed ID: 26147106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
    Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
    Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.